A biopsy is a tissue or cell sample taken from any part of the patient’s body and examined in the lab for the detection of cancer. Liquid biopsy offers a real-time approach for the treatment of breast cancer. It is used for the collection and analysis of a sample of blood taken from the patient. Liquid biopsy uses body fluids as a sample for analysis, primarily blood. It analyses the presence of tumor cell-derived biomarkers such as circulating tumor cells, cell-free DNA (cfDNA) and their cargo proteins, and circulating cell-free RNA (cfRNA). A liquid biopsy is a noninvasive, simple, and cost-effective diagnostic tool for cancer. The amount of circulating biomarkers differ among cancer patients and healthy individuals. Therefore, these circulating biomarkers act as an important tool for both early diagnosis and monitoring of the progression of disease in advanced cancer stages to analyse the heterogeneity of tumor cells. Breast cancer is considered to be the second most common malignancy in the world, and therefore, liquid biopsy is a very important tool for breast cancer diagnosis and determination.
Request Brochure –
According to the World Health Organization (WHO), breast cancer is the most frequently occurring cancer among women. It affects 2.1 million women each year and results in the highest number of cancer-related deaths among women. In 2018, it was evaluated that 627,000 women died from breast cancer, i.e. around 15% of all cancer-related deaths among women. While rates of breast cancer are higher among women in more developed regions, rates are elevating in nearly every region globally.
Key drivers of the breast cancer liquid biopsy market include rise in the prevalence of breast cancer, increase in propensity for non-invasive procedures, rise in awareness about cancer, increase in health care expenditure, and initiatives and measures taken by government and global health organizations. Moreover, intensive research and development in the field of cancer, technological advancements, and an inclination toward personalized medicine are expected to enhance the growth of the market. However, insufficiency of trained professionals, high cost of the tests, and fewer reimbursement policies are expected to hinder the global breast cancer liquid biopsy market.
Request COVID Analysis on Liquid Biopsy Market –
Based on circulating biomarkers, the global breast cancer liquid biopsy market can be classified into cell-free DNA (cfDNA), circulating tumor cells (CTCs), extracellular vesicles (EVs), and other circulating biomarkers. The cell-free DNA (cfDNA) segment is expected to hold a prominent share of the breast cancer liquid biopsy market. This is because of rise in research in breast cancer using cfDNA for the diagnosis of the disease and therapeutic monitoring. In terms of end-user, the global breast cancer liquid biopsy market can be categorized into reference laboratories, hospitals and physician laboratories, and other end-users. Other end-users comprise research institutes, academic research laboratories, pathology laboratories, etc. Reference laboratories is expected to be a prominent end-user segment, accounting for a significant share of the breast cancer liquid biopsy market. This is due to a rise in the number of liquid biopsy test samples received by reference laboratories for genetic testing because of their well-equipped set-up.
Based on geography, the global breast cancer liquid biopsy market can be segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America and Europe accounted for a prominent share of the global breast cancer liquid biopsy market due to the presence of a number of biopharmaceutical companies research and academic institutes. Asia Pacific is expected to be a rapidly expanding region of the breast cancer liquid biopsy market due to a large population base, increased prevalence of cancer, and rise in investments by leading market players and hospitals.
Pre Book Liquid Biopsy Market Report –
Key players operating in the global breast cancer liquid biopsy market are Qiagen, Bio-Rad Laboratories, Inc., F. Hoffmann-La Roche Ltd, Myriad Genetics, Inc., Illumina, Inc., Thermo Fisher Scientific Inc., Genomic Health, Menarini Silicon Biosystems, Cynvenio Biosystems, Inc., Guardant Health, INC , Biodesix, Inc., and Isogen Life Science B.V. among others. In order to gain a competitive advantage in the market, key players are actively involved in various growth strategies such as agreements, partnerships and collaborations, and new product development.
Transparency Market Research is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants, use proprietary data sources and various tools and techniques to gather, and analyze information.
Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.
Transparency Market Research,
90 Sate Street, Suite 700,
Albany, NY 12207
USA – Canada Toll Free: 866-552-3453
Email: [email protected]om